Patent US4060436A successfully refreshed from Google Patents.
Patent US5523232A successfully refreshed from Google Patents.
US5523232A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of restriction endonucleases against viruses, including HIV
Assignee: United States Department of Health and Human Services
•
Filing: 1994-06-08
•
Granted: 1996-06-04
•
Expires: 2014-06-08
Abstract
Abstract Restriction endonucleases are administered to a patient topically or internally to prevent or ameliorate viral infection. The endonucleases are also useful to treat products, such as blood and blood derived products, to eliminate viral transmission when the products are administered to a patient. In addition, the endonucleases may be used in the manner of a disinfectant to inactivate viral contamination on objects. The endonucleases are used in their native form, modified to provide decreased immunoreactivity or increased ability to target a site of infection or both, and alone or in combination with a suitable excipient. In addition to methods of treatment and disinfection, the invention provides related products, such as pharmaceutical compositions.
Inventors
- 👤 Joan M. Sechler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:52
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/16; C12N9/22; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K38/00
Claims Analysis
Total Claims: 45
Claim 1
Independent Claim
47 words
A method for inhibiting propagation of a virus, comprising the step of administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said moiety displays endonucleolytic activity toward the DNA of said virus.
Claim 2
Independent Claim
47 words
A method for inhibiting propagation of a virus, comprising the step of administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said moiety displays endonucleolytic activity toward the DNA of said virus.
Claim 3
Dependent Claim
13 words
The method of claim 1, wherein said composition comprises a pharmaceutically acceptable excipient.
Claim 4
Independent Claim
55 words
A method for inhibiting propagation of a virus, comprising the step of administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said moiety displays endonucleolytic activity toward the DNA of said virus, wherein said compound is encapsulated in a liposome.
Claim 5
Independent Claim
55 words
A method for inhibiting propagation of a virus, comprising the step of administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said moiety displays endonucleolytic activity toward the DNA of said virus, wherein said compound is encapsulated in a liposome.
Claim 6
Dependent Claim
21 words
The method of claim 3, wherein said compound is modified to decrease deleterious immunological side effects compared with the unmodified compound.
Claim 7
Dependent Claim
11 words
The method of claim 2, wherein said composition is administered internally.
Claim 8
Dependent Claim
17 words
The method of claim 5, wherein said composition is administered intradermally, subcutaneously, intramuscularly, intraperitoneally, intraarterially or intravenously.
Claim 9
Dependent Claim
20 words
The method of claim 6, wherein said compound is modified to decrease deleterious immunological side effects compared with unmodified compound.
Claim 10
Dependent Claim
14 words
The method of claim 7, wherein said compound is substantially free of N-formyl methionine.
Claim 11
Dependent Claim
18 words
The method of claim 7, wherein said compound is modified by conjugation to polyethylene glycol or polypropylene glycol.
Claim 12
Dependent Claim
10 words
The method of claim 2, wherein said virus is HIV.
Claim 13
Dependent Claim
19 words
The method of claim 10, wherein said restriction endonuclease moiety provides the endonucleolytic activity of the BglII restriction endonuclease.
Claim 14
Dependent Claim
11 words
The method of claim 2, wherein said virus is hepatitis B.
Claim 15
Dependent Claim
33 words
The method of claim 1, wherein said compound comprises an antigen specific binding region for localizing the endonucleolytic activity of said compound at a target site of infection where said antigen is located.
Claim 16
Dependent Claim
12 words
The method of claim 13, wherein said antigen is a HIV antigen.
Claim 17
Dependent Claim
51 words
An ex vivo method to inactivate virus in blood or a blood derived composition, comprising the step of exposing said blood or blood-derived composition to a compound comprised of a moiety of a restriction endonuclease that provides endonucleolytic activity of a type and in an amount effective to inactivate a virus.
Claim 18
Dependent Claim
51 words
An ex vivo method to inactivate virus in blood or a blood derived composition, comprising the step of exposing said blood or blood-derived composition to a compound comprised of a moiety of a restriction endonuclease that provides endonucleolytic activity of a type and in an amount effective to inactivate a virus.
Claim 19
Dependent Claim
60 words
A ex vivo method to inactivate virus in blood or a blood derived composition, comprising the step of exposing said blood or blood-derived composition to a compound comprised of a moiety of a restriction endonuclease that provides endonucleolytic activity of a type and in an amount effective to inactivate a virus, wherein said restriction endonuclease is encapsulated in a liposome.
Claim 20
Dependent Claim
60 words
A ex vivo method to inactivate virus in blood or a blood derived composition, comprising the step of exposing said blood or blood-derived composition to a compound comprised of a moiety of a restriction endonuclease that provides endonucleolytic activity of a type and in an amount effective to inactivate a virus, wherein said restriction endonuclease is encapsulated in a liposome.
Claim 21
Dependent Claim
32 words
The method of claim 15, wherein said compound is modified to decrease deleterious immunological side effects compared with the unmodified compound when said blood or blood-derived composition is administered to a patient.
Claim 22
Dependent Claim
16 words
The method of claim 15, wherein said compound is conjugated to polyethylene glycol or polypropylene glycol.
Claim 23
Dependent Claim
21 words
The method of claim 18, wherein said virus is selected from the group consisting of HIV, hepatitis B and hepatitis C.
Claim 24
Dependent Claim
22 words
The method of claim 19, wherein said virus is the HIV virus and said endonucleolytic activity is that of the BglII endonuclease.
Claim 25
Dependent Claim
57 words
A pharmaceutical composition for topical administration, comprising: (A) a substantially pure and pyrogen-free compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus at a site of infection to which said composition is applied; and (B) a pharmaceutically acceptable excipient for topical administration.
Claim 26
Dependent Claim
57 words
A pharmaceutical composition for topical administration, comprising: (A) a substantially pure and pyrogen-free compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus at a site of infection to which said composition is applied; and (B) a pharmaceutically acceptable excipient for topical administration.
Claim 27
Dependent Claim
14 words
The composition of claim 21, wherein said compound is substantially non-immunogenic for topical application.
Claim 28
Dependent Claim
14 words
The composition of claim 22, wherein said compound is substantially free of N-formyl methionine.
Claim 29
Dependent Claim
16 words
The composition of claim 22, wherein said compound is conjugated to polyethylene glycol or polypropylene glycol.
Claim 30
Dependent Claim
52 words
A pharmaceutical composition for systemic administration, comprising: (A) a substantially pure and pyrogen free compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus at a site of infection; and, (B) a pharmaceutically acceptable excipient for systemic administration.
Claim 31
Dependent Claim
52 words
A pharmaceutical composition for systemic administration, comprising: (A) a substantially pure and pyrogen free compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus at a site of infection; and, (B) a pharmaceutically acceptable excipient for systemic administration.
Claim 32
Dependent Claim
14 words
The composition of claim 25, wherein said compound is substantially non-immunogenic for systemic application.
Claim 33
Dependent Claim
14 words
The composition of claim 26, wherein said compound is substantially free of N-formyl methionine.
Claim 34
Dependent Claim
16 words
The composition of claim 26, wherein said compound is conjugated to polyethylene glycol or polypropylene glycol.
Claim 35
Dependent Claim
46 words
A disinfectant composition, comprising: (A) a compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus when applied to an object to be disinfected; and (B) an inert carrier for disinfectant application.
Claim 36
Dependent Claim
46 words
A disinfectant composition, comprising: (A) a compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward the DNA of a virus when applied to an object to be disinfected; and (B) an inert carrier for disinfectant application.
Claim 37
Independent Claim
49 words
A method for inhibiting propagation of a virus, comprising the step of topically administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward DNA of said virus.
Claim 38
Independent Claim
49 words
A method for inhibiting propagation of a virus, comprising the step of topically administering to a patient in a therapeutically effective amount a composition comprising a compound comprised of a moiety of a restriction endonuclease such that said restriction endonuclease moiety displays endonucleolytic activity toward DNA of said virus.
Claim 39
Dependent Claim
14 words
The method of claim 30, wherein said composition further comprises a pharmaceutically acceptable excipient.
Claim 40
Dependent Claim
21 words
The method of claim 31, wherein said compound is modified to decrease deleterious immunological side effects compared with the unmodified compound.
Claim 41
Dependent Claim
14 words
The method of claim 30, wherein said compound is substantially free of N-formyl methionine.
Claim 42
Dependent Claim
18 words
The method of claim 30, wherein said compound is modified by conjugation to polyethylene glycol or polypropylene glycol.
Claim 43
Dependent Claim
10 words
The method of claim 31, wherein said virus is HIV.
Claim 44
Dependent Claim
17 words
The method of claim 35, wherein said moiety provides the endonucleolytic activity of the BglII restriction endonuclease.
Claim 45
Dependent Claim
11 words
The method of claim 31, wherein said virus is hepatitis B.
References Cited (Backward Citations)
US4179337A
Cited
US4895724A
Cited
EP0234781A2
Cited
US5006333A
Cited
US5190762A
Cited
WO1992012237A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-06-04 | 1999-12-04 | 2000-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-06-04 | 2003-12-04 | 2004-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-06-04 | 2007-12-04 | 2008-06-04 | $7700.00 | Window Closed / Lapsed |